Taxotere (R) offers significant survival benefits for head and neck cancer patients


BRIDGEWATER, NJ – June 5, 2004 – Aventis announced today the results of a phase III trial using TaxotereŽ (docetaxel) Injection Concentrate when added to a standard therapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in New Orleans, LA. Investigators reported that the TaxotereŽ-based regimen demonstrated superior overall survival rates, and patients also benefited from significantly improved progression-free survival and cancer response rates, as well as a lower rate of severe side effects compared to the standard therapy.

The trial, conducted by the European Organization for Research and Treatment of Cancer (EORTC) Head and Neck Cooperative Group, involved 358 patients and demonstrated that patients receiving TaxotereŽ plus cisplatin and 5-fluorouracil (5-FU) had significant prolongation of progression-free survival, the trial's primary endpoint, (12.7 months vs. 8.4 months, p=0.006) compared to those who received the standard treatment of cisplatin and 5-fluorouracil (5-FU). The TaxotereŽ combination also resulted in significantly improved overall survival (18.6 months vs. 14.5 months, p=0.016) and significantly increased overall response rates (67.8 percent vs. 53.6 percent, p=0.007), the trial's secondary endpoints.

"Head and neck cancer patients have very limited treatment options. The addition of TaxotereŽ to this standard treatment regimen is very encouraging and may change the paradigm by which we treat this disease," said Jan B. Vermorken, MD, PhD, EORTC Principal Investigator, Professor of Oncology and Head of the Department of Medical Oncology at the University Hospital of the University of Antwerp in Belgium. "The trial findings provide new important information for oral surgeons, medical oncologists and radiation oncologists."

Head and neck cancer is the seventh most frequently occurring cancer worldwide with an incidence rate of 390,000 cases annually. In the United States, it is estimated that more than 38,000 cases will occur in 2004.

"We are encouraged by today's results that suggest a benefit with TaxotereŽ for patients with advanced head and neck cancer, a difficult to treat disease," said Frank Douglas, MD, PhD, Executive Vice President of Drug Innovation and Approval and a Member of the Board of Management at Aventis.

Study Results and Protocol

Patients in the multicenter trial were randomly assigned to receive one of two treatments. Of the 358 participants, 177 received an infusion of TaxotereŽ plus cisplatin on day one and a five-day continuous infusion of 5-fluorouracil (5-FU) and 181 patients received an infusion of a standard treatment consisting of cisplatin on day one followed by a five-day continuous infusion of 5-fluorouracil (5-FU). Treatment cycles were to be repeated every three weeks for a total of four cycles. All patients received radiation therapy following chemotherapy within four to seven weeks after completing the last cycle of chemotherapy. Radiation therapy was administered five days a week for up to seven weeks.

In this trial, investigators reported that TaxotereŽ regimen was well tolerated and had a generally predictable and manageable safety profile. Patients receiving the cisplatin and 5-fluorouracil (5-FU) regimen showed greater grade 3-4 nausea (7.3 percent vs. 0.6 percent), vomiting (5.0 percent vs. 0.6 percent) stomatitis (11.2 percent vs. 4.6 percent) and more toxic deaths (5.5 percent vs. 2.3 percent) when compared to the TaxotereŽ regimen.

These results are one of three large randomized phase III TaxotereŽ studies highlighted at this premier oncology meeting from which investigators reported survival advantages for cancer patients. Also two landmark phase III trials, TAX 327 (abstract 4) and SWOG 9916 (abstract 3), demonstrated a TaxotereŽ-based regimen yielded a statistically significant survival benefit for men with androgen-independent (hormone-refractory) metastatic prostate cancer.

About Taxotere

TaxotereŽ, a drug in the taxoid class of chemotherapeutic agents, inhibits cancer cell division by essentially "freezing" the cell's internal skeleton, which is comprised of microtubules. Microtubules assemble and disassemble during a cell cycle. TaxotereŽ promotes their assembly and blocks their disassembly, thereby preventing many cancer cells from dividing and resulting in cancer cell death.

TaxotereŽ is currently approved in the United States to treat patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy, and patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin, who had not received prior chemotherapy. It also is approved for patients with unresectable locally advanced or metastatic NSCLC after failure of prior platinum-based chemotherapy. On May 19, 2004, the U.S. Food and Drug Administration granted approval of TaxotereŽ for use in combination with prednisone as a treatment for men with androgen-independent (hormone-refractory) metastatic prostate cancer.

Among patients receiving TaxotereŽ the most common severe adverse events were low blood cell count, fatigue, diarrhea, and mouth and throat irritation.

The most common non-severe side effects include hair loss, numbness, a tingling and/or burning sensation, rash, nail changes, nausea, vomiting, and muscle pain.

Less common severe or potentially life threatening side effects include fluid retention, infections, and allergic reactions.

Patients 65 years of age or older may experience some side effects more frequently. For more information about TaxotereŽ, visit or see full prescribing information including boxed WARNING.

Source: Eurekalert & others

Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on All rights reserved.